semaglutide shortage news november 2025 Is There A Shortage? Ozempic and Wegovy Availability Updates GLP-1 No Longer on FDA's

Pfizer is targeting 2028 for its first regulatory approval in the obesity market

The Summary of Product Characteristics does not include sleep disturbances, insomnia, or related terms among the documented adverse reactions from clinical trials or post-marketing surveillance data

Additionally, these nutrients help to maintain low levels of homocysteine, a potentially toxic chemical that can lead to stroke and atherosclerosis

Binghamton (NY): Haworth Medical Press

Nevertheless, given residual heterogeneity and the inherent limitations of network meta-analyses, further randomized trials are needed to confirm these findings, define relative effects versus individual GLP-1RAs, and clarify the role of tirzepatide across broader cardiometabolic populations

Jeffrey I